Optiver Holding
PTGX icon

Optiver Holding’s Protagonist Therapeutics PTGX Stock Holding History

Optiver Holding’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.4K Buy
+436
New +$45.5K ﹤0.01% 1150
2025
Q4 		– Sell
-169
Closed -$11.2K – 2877
2025
Q3 		$11.2K Buy
+169
New +$9.61K ﹤0.01% 1224
2025
Q2 		– Sell
-11
Closed -$532 – 1602
2025
Q1 		$532 Buy
+11
New +$461 ﹤0.01% 1303

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Optiver Holding's PTGX Position: Q2 2026 in Review

Optiver Holding opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 436 shares worth $53.4K. The stake represents ﹤0.01% of the portfolio and ranks #1150 among its holdings. This is a return to the name: Optiver Holding previously reported a position in PTGX as recently as Q3 2025.

Optiver Holding first reported a position in PTGX in Q1 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Optiver Holding held 436 shares of Protagonist Therapeutics worth $53.4K as of Q2 2026.
  • Protagonist Therapeutics was a new Optiver Holding position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1150 holding.
  • Optiver Holding first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.